Skip to main content

Table 3 Experiment 2: losses after intravenous injection, relative concentrations and actual doses after direct subcutaneous injection of different formulations of interferon β-1a

From: Biases affecting injected doses of an experimental drug during clinical trials

Formulation Losses after intravenous injection Relative concentration (direct subcutaneous injection) Actual dose [MIU] (direct subcutaneous injection)
  Median Range Median Range Median Range
Biferonex® HSA-free 5.6 % 0.6 % 167 % 3 % 18.01 0.02
Biferonex® + HSA 13.6 % 6.5 % 173 % 8 % 16.74 0.05
Rebif® 5.7 % 9.1 % 131 % 19 % 18.33 0.01
  1. Losses observed after injection through the infusion line (intravenous) versus direct injection (subcutaneous) of three different formulations of interferon β-1a at a dose of 18.0 MIU. Relative concentrations are expressed with reference to nominal levels